title: Misleading data in pharmaceutical and biological patent specifications: best mode after the America Invents Act.
authors.affiliation: Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210, USA.
authors.forename: Claire
authors.initials: C
authors.lastname: Laporte
authors.affiliation: Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210, USA.
authors.forename: Catherine C
authors.initials: CC
authors.lastname: Deneke
authors.affiliation: Sarepta Therapeutics Inc., Cambridge, MA, USA.
authors.forename: Damon
authors.initials: D
authors.lastname: Banks
mesh_terms: D001688:Biological Products / Q000145:classification* / Q000592:standards; D004345:Drug Industry / Q000145:classification* / Q000379:methods / Q000592:standards; D006801:Humans; D062069:Inventions / Q000145:classification* / Q000592:standards; D010330:Patents as Topic; D004364:Pharmaceutical Preparations / Q000145:classification* / Q000592:standards; D013223:Statistics as Topic / Q000145:classification* / Q000592:standards; D014481:United States
chemical_list: D001688:Biological Products; D004364:Pharmaceutical Preparations
keywords: America Invents Act; best mode; enablement; inequitable conduct; lysine; patents; written description